Skip to main content
. Author manuscript; available in PMC: 2011 Jul 12.
Published in final edited form as: Clin Gastroenterol Hepatol. 2008 Jul 25;6(11):1243–1248. doi: 10.1016/j.cgh.2008.07.013

Table 3.

Histologic changes in placebo-treated patients with NASH: Pooled results.

Variable Study (year) Duration (months) Delta Mean % Patients with Any Improvement % Patients with 2-Point Improvement P-value
Steatosis (n=124) Belfort (2006) 6 −0.29 38.1% (8/21) 0% (0/21)
Merat (2003) 6 -- -- --
Ratziu (2008) 12 −0.16 16.1% (5/31)
Dufour (2006) 24 −0.50 -- --
Lindor (2004) 24 −0.30 36.8% (21/57) 1.8% (1/57)
Combined 0.31 31.2% (34/109) 1.3% (1/78) <0.001
Ballooning degeneration (n=124) Belfort (2006) 6 −0.19 23.8% (5/21) 4.8% (1/21)
Merat (2003) 6 -- -- --
Ratziu (2008) 12 0.23 9.7% (3/31) 0% (0/31)
Dufour (2006) 24 0.17 -- --
Lindor (2004) 24 −0.10 14.0% (8/57) 1.8% (1/57)
Combined 0.03 14.7% (16/109) 1.8% (2/109) 0.68
Lobular inflammation (n=67) Belfort (2006) 6 −0.29 28.6% (6/21) 0% (0/21)
Merat (2003) 6 -- -- --
Ratziu (2008) 12 −0.13 35.5% (11/31)
Dufour (2006) 24 0.17 -- --
Lindor (2004) 24 -- -- --
Combined 0.08 32.7% (17/52) 0% (0/21) 0.19
NASH fibrosis (n=122) Belfort (2006) 6 −0.14 33.3% (7/21) 4.8% (1/21)
Merat (2003) 6 -- -- --
Ratziu (2008) 12 −0.18 16.1% (5/31)
Dufour (2006) 24 0.05 -- --
Lindor (2004) 24 0.00 21.8% (12/55) 3.6% (2/55)
Combined 0.07 22.4% (24/107) 3.9% (3/76) 0.44
Combined Necro-inflammation or Nash Activity Score (n=107) Belfort (2006) 6 -- 38.1% (8/21) 14.3% (3/21)
Merat (2003) 6 -- -- --
Ratziu (2008) 12 -- 41.9% (13/31)
Dufour (2006) 24 -- -- --
Lindor (2004) 24 -- 23.6% (13/55) 5.5% (3/55)
Combined -- 31.8% (34/107) 7.9% (6/76) 0.12

n, Number of patients that could be used to calculate Deltas and P-values out of a total N=162.